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PRÁTICA CLINICA
ted online on the level of agreement with the updated
recommendations.
Results: Results presented in this article are mainly in
accordance with previous guidelines, with some new
information regarding hepatitis B infection during MTX
treatment, pulmonary toxicity monitoring, hepatotoxi -
city management, association with hematologic neo-
plasms, combination therapy and tuberculosis scree -
ning during treatment. 
Conclusion: The present recommendations combine
scientific evidence with expert opinion and attained de-
sirable agreement among Portuguese rheumatologists.
The regular update of these recommendations is essen -
tial in order to keep them a valid and useful tool in dai-
ly practice. 
Keywords: Recommendations; Rheumatoid arthritis;
Portugal; Rheumatic diseases; Methotrexate
INtrODUctION
Methotrexate (MTX) is the first line drug in the treat-
ment of rheumatoid arthritis (RA) and the most com-
monly prescribed conventional synthetic disease modi -
fying anti-rheumatic drug (csDMARD). Moreover, it is
also used as an adjuvant drug in patients under biolo -
gic therapies, enhancing the efficacy of biologic agents1.
According to Rheumatic Disease Portuguese Regis-
ter (Reuma.pt) annual report, in 2015 only 7.35% of
the rheumatoid arthritis patients were treated with
biolo gics in monotherapy. MTX was administered to
76.2% of the rheumatic patients registered in Reu -
ma.pt2.
The multinational 2007-2008 3E Initiative (Evi-
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AbstrAct
Background: Methotrexate (MTX) is the first-line drug
in the treatment of rheumatoid arthritis (RA) and the
most commonly prescribed disease modifying anti-
rheumatic drug. Moreover, it is also used as an adjuvant
drug in patients under biologic therapies, enhancing
the efficacy of biologic agents.
Objectives: To review  the literature and update the
Portuguese recommendations for the use of MTX in
rheumatic diseases first published in 2009.
Methods: The first Portuguese guidelines for the use of
MTX in rheumatic diseases were published in 2009 and
were integrated in the multinational 3E Initiative (Evi -
dence Expertise Exchange) project. The Portuguese
rheumatologists based on literature evidence and con-
sensus opinion formulated 13 recommendations. At a
national meeting, the recommendations included in
this document were further discussed and updated.
The document resulting from this meeting circulated to
all Portuguese rheumatologists, who anonymously vo -
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dence Expertise Exchange) included rheumatologists
from 17 countries who worked on recommendations
for the management of MTX use in several clinical sce-
narios3. Therefore, its main objective was to develop
practical recommendations for the use of MTX in
rheumatic diseases, integrating systematically gene -
rated evidence and expert opinion of a broad panel of
international rheumatologists. The guidelines were
published in 2009, providing a total of 10 recommen-
dations3.
Within this effort, the Portuguese delegates elected
three relevant questions for their practice, which were
not covered by the multinational recommendations. It
was performed a systematic literature review regarding
these questions, in agreement with the 3E Initiative
project and procedures4,5.
The Portuguese recommendations for the use of
MTX were published in 2009 with 13 recommenda-
tions, including the 10 international recommendations
(with specific aspects considering the Portuguese con-
text) and three additional national recommendations4.
This article presents the 2016 update of the Por-
tuguese recommendations for the use of MTX in
rheumatic diseases.
MEtHODs
We performed a comprehensive search for systematic
literature reviews (SLR) and meta-analysis published
after 2007 (after the original international SLR and the
additional Portuguese SLR). The search strategies were
designed to be broad enough to cover studies addres -
sing all the recommendations questions.
We searched Medline (until 10 August 2015), Em-
base (until 10 August 2015) and Cochrane (until 18
August 2015) databases.
The inclusion criteria for SLR were: SLR/ meta-
analy sis addressing efficacy and/ or safety of MTX
(alone or in combination with other csDMARDs) in
adult patients with RA, psoriatic arthritis (PsA) or 
other rheumatic diseases, namely polymyositis
(PM)/dermatomyositis (DM), polymyalgia rheumatic
(PMR), systemic lupus erythematous (SLE) and vascu -
litis. The exclusion criteria for SLR were inadequate
type of article (reviews that were not systematic, edito -
rials, conference abstracts or opinion papers were not
included to avoid duplicate information); wrong popu -
lation (not a rheumatic disease) or intervention (not
MTX alone or in combination with other csDMARD);
and languages (other than English or Portuguese).
The references of the included studies were submit -
ted to detailed review and screened for studies related
to each of the 13 questions. We performed a comple-
mentary hand search for each question.
Furthermore, the new evidence was graded ac-
cording to the levels of evidence of the Oxford Centre for
Evidence-Based Medicine6 and compared to the previous
level of evidence.
The Portuguese rheumatologists based on literature
evidence and consensus opinion formulated these
recom mendations. A draft and respective supporting
evidence was first circulated to all Portuguese rheuma-
tologists. Secondly, at a national meeting, the recom-
mendations were presented, discussed and revised. Fi-
nally, the document resulting from this meeting was
again circulated to all Portuguese rheumatologists, who
anonymously voted online on the level of agreement
with the recommendations (total of 79 participants).
Agreement was measured on a 10-point numerical ra -
ting scale (1=no agreement, 10=full agreement).
rEsULts
The flowchart for the systemic literature search and re-
sults of the selection process are presented in Figure 1.
On the first search we retrieved 1499 articles, fol-
lowed by the elimination of duplicates, with 1161 ar-
ticles identified. After title and abstract selection, fol-
lowed by the detailed review, 45 SLR/meta-analysis
were obtained. The references of the included studies
identified 128 new articles, submitted subsequently to
detailed review. 
The articles were selected and screened according to
the specific inclusion and exclusion criteria for each
of the questions, with 47 articles included, after an ad-
ditional hand search (Figure 1).
Table I summarizes the distribution of the included
papers according to the question and respective levels
of evidence, in 2009 and 2015.
rEcOMMENDAtIONs
Thirteen recommendations were formulated, reaching
high level of agreement among Portuguese rheuma-
tologists (Table II).
In all recommendations new information is high-
lighted in bold.
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rEcOMMENDAtION 1
What pre-administration work-up is needed
(comorbidities/ social behaviour, physical,
laboratory and radiographic data) to identify
MTX contra-indications and/or get a baseline
evaluation?
The work-up for patients starting MTX should include pa-
tient education, clinical assessment of risk factors for MTX
toxicity (including alcohol intake), levels of aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
albumin, complete blood count (CBC), creatinine, serolo-
gy for hepatitis B virus (HBV), consider serology for hu-
man immunodeficiency virus (HIV) and hepatitis C, blood
fasting glucose, lipid profile, pregnancy test, chest x-ray
(obtai ned within the previous year); and body mass index
(BMI).
Screening for HBV infection and careful monitoring
during the use of MTX are important because MTX
can induce HBV reactivation in patients with
chronic HBV infection and, possibly, also in patients
with past/’resolved’ HBV infection. 
In early RA patients, increased ALT, AST and creatinine
levels at the start of the treatment were associated with
liver toxicity at follow-up7. Furthermore, high BMI was
associated with withdrawal due to MTX-related adverse
events (AEs)7. A case–control study8 has shown an as-
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FIGUrE 1. Flowchart for the systematic literature search and results of the selection process
SLR: systematic literature review
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drugs, specifically for MTX (OR: 4.9; 95% confidence
interval (CI): 3.9-6.0). Six of 92 (6.5%) HBV reactiva-
tions on patients receiving antirheumatic drugs were
reported as fulminant hepatitis and among these, four
(66.7%) occurred in patients treated with MTX. Ne -
vertheless, fatal HBV cases were mostly observed in pa-
tients who received a combination of two or more 
csDMARDs. However, due to the lack of detailed in-
formation pertaining to antibody/antigen status prior to
treatment, it is not possible to understand if HBV-reacti -
vation occurred in patients who were HBsAg-positive
or also in HBsAg-negative patients8.
rEcOMMENDAtION 2
What is the best dosing strategy and route of
administration of MTX in patients with RA to
optimize an early response and minimize
toxicity?
Oral MTX should be started at 10–15 mg/week, with esca-
lation of 5 mg every two to four weeks up to 25 mg/week,
depending on clinical response and tolerability; parenteral
administration should be considered in the case of inade-
quate clinical response or intolerance. 
Starting MTX therapy by parenteral route may be an
option.
Data concerning the starting dose described in a Ran-
domized controlled trial (RCT)9 do not support the use
of a high starting dose (25 mg) strategy for oral MTX
treatment, compared to a standard starting dose (15
mg). Pharmacokinetic parameters were significantly
higher with 25mg/week than with 15mg/week, but
without any measurable clinical advantage. There were
no differences between groups in minor and self-limi -
ted AEs, however given the small sample size (n=19),
this study was not powered to detect differences in the
incidence of AEs.
A two-year RCT7,10 in early RA, comparing intensive
dose escalation of 5mg/week monthly with dose esca-
lation of 5mg/week three-monthly, has found that, in
spite of the more frequently occurrence of AEs in the
intensive strategy group, their severity was relatively
mild and the observed clinical efficacy seemed to out-
weigh the toxicity profile7. Furthermore, the switch
from oral MTX to subcutaneous (SC) was effective,
when facing insufficient response, probably due to the
higher bioavailability compared to oral MTX10.
The use of SC MTX and higher maximum MTX dose
(>15 mg/week) were independently associated with
higher likelihood to remain on MTX monotherapy,
while older age and renal failure limited the use of hi -
gher MTX maximum dosages11. An observational
study12 has shown that patients on parenteral therapy
were younger and were more likely to have extreme
tAbLE I. NUMbEr OF INcLUDED pApErs AND LEvEL OF EvIDENcE IN 2009 AND 2016 FOr EAcH 
rEcOMMENDAtION
2009 number 2009 level 2016 number of 2016 level of 
Recommendation of papers of evidence* new publications evidence 2016¥
1. Pre-MTX workup 52 5 1 4
2. Dose and route 50 5 6 2
3. Folic acid 9 1b 3 2
4. Monitoring 23 5 2 4
5. Hepatotoxicity 46 2a 3 4
6. Long-term safety 88 2b 10 2
7. Mono vs combination 20 1b 2 1
8. Corticosteroid sparing effect 6 1b 3 1
9. Surgery 4 2b 1 2
10. Pregnancy 6 5 4 3
11. Remission 1 5 6 2
12. Infections 11 4 2 3
13. Tuberculosis 1 5 4 5
Total 317 47
*Oxford Centre for Evidence-Based Medicine. Levels of evidence. 1995. ¥ OCEBM Levels of Evidence Working Group(6)
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tAbLE II. rEcOMMENDAtIONs FOr tHE UsE OF MEtHOtrExAtE IN rHEUMAtIc DIsEAsEs – 2016 UpDAtE
Level of Grade of Agreement (0-10)
Recommendations evidence recommendation mean (SD)
1. The work-up for patients starting MTX should include patient 4 C 8.7 (1.7)
education, clinical assessment of risk factors for MTX toxicity 
(including alcohol intake), levels of aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), albumin, complete blood 
count (CBC), creatinine, serology for hepatitis B virus (HBV), 
consider serology for human immunodeficiency virus (HIV) and 
hepatitis C, blood fasting glucose, lipid profile, pregnancy test, 
chest x-ray (obtained within the previous year); and body 
mass index (BMI).
Screening for HBV infection and careful monitoring during the 
use of MTX are important because MTX can induce HBV 
reactivation in patients with chronic HBV infection and, possibly, 
also in patients with past/’resolved’ HBV infection. 
2. Oral methotrexate should be started at 10–15 mg/week, with 2 B 8.9 (1.7)
escalation of 5 mg every two to four weeks up to 25 mg/week,
depending on clinical response and tolerability; parenteral
administration should be considered in the case of inadequate
clinical response or intolerance.
Starting MTX therapy by parenteral route may be an option.
3. Folic acid supplementation is strongly indicated for reducing 2 B 8.9 (1.8)
GI side effects of MTX, particularly transaminases elevation, in a
recommended dose of 5-10 mg in one to two doses per week.
Folinic acid seems to have the same efficacy as folic acid, but with
a higher cost, making it a less cost-effective treatment.
There is no data regarding the ideal time interval between MTX
and folic acid administration.
4. After four to six weeks of treatment beginning or escalation, 4 C 8.8 (1.6)
ALT, AST, CBC and creatinine should be performed. Thereafter,
if a stable dose of MTX is reached, the same analytical evaluation
should be performed every three to four months. Clinical
assessment should be performed at each visit.
Pulmonary function tests (PFTs) are not recommended on a
routine basis, neither previous to MTX-treatment start, nor
during therapy.
5. MTX should be transiently stopped or its dose lowered if AST 4 C 8.7 (1.6)
and/or ALT is greater than two times the upper limit of normal
(ULN) in three consecutive monthly laboratorial evaluations
(other causes of transaminase elevation must be ruled out). MTX
can be reinstituted after transaminase levels return to normal.
MTX should never be readministered to patients with clinical
hepatitis without any other apparent cause, in whom
transaminase levels remain persistently elevated even after
MTX temporary discontinuation.
Liver fibrosis is more likely in patients taking MTX if
concomitant predisposing factors for hepatotoxicity are present,
including diabetes mellitus, obesity and alcohol consumption.
Therefore, these patients should be carefully monitored, and
modifiable risk factors corrected. Treatment decision should be
taken in collaboration with a hepatologist.
continues on the next page
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values of BMI than those on oral therapy. The response
to parenteral therapy were predicted by low BMI (<22
Kg/m2), possibly due to malabsorption, or by high BMI
(>30 Kg/m2) maybe as a result of gastrointestinal into -
lerance (mainly symptoms of gastro-oesophageal re-
flux disease) with oral therapy12. In RA patients who
have failed to achieve an adequate response to oral
MTX, as result of intolerance or resistance, the majori -
ty (74%) achieved response [decreased disease activi-
ty scores (DAS) scores by at least 1.2] after switching
tAbLE II. cONtINUAtION
Level of Grade of Agreement (0-10)
Recommendations evidence recommendation mean (SD)
6. MTX can be used for long-term treatment and its use is safe as 2 B 9.1 (1.6)
far as risk of infectious and cardiovascular diseases is concerned.
Surveillance of pulmonary toxicity and of lymphoproliferative
disorders is advised.
7. In DMARD-naive patients the balance of efficacy/toxicity 1 B 8.9 (1.5)
favours methotrexate monotherapy over combination with
other conventional DMARD; methotrexate should be considered
as the anchor for combination therapy when methotrexate
monotherapy does not achieve disease control.
In early RA consider implementation of a tight control and rapid
step-up strategy with MTX plus low-dose PDN (≤10mg/day)
for up to six months.
8. MTX can be considered as a steroid-sparing agent in giant-cell 1 A 9.0 (1.7)
arteritis, PMR, SLE and juvenile DM.
9. Methotrexate can be safely continued in the perioperative 2 C 8.7 (2.1)
period in RA patients undergoing elective orthopaedic surgery.
Still no data regarding MTX dose management in patients
undergoing (non-) elective non-orthopaedic surgery.
10. We recommend MTX suspension at least three months 3 B 8.7 (1.7)
before conception, during pregnancy and breastfeeding. In men,
when MTX therapy is unavoidable, there is recent evidence that
MTX doesn´t need to be stopped before conception.
Previous use of MTX was not associated with fertility problems
in female and male RA patients, as assessed by time to pregnancy.
11. A gradual dose reduction to the lowest effective MTX dose 2 B 8.0 (2.1)
may be attempted after achieving sustained clinical remission
for at least 6 months, with clinical and radiological monitoring.
In some early RA patients in remission, drug-free remission
may be achieved, but it could be associated with an increased
risk of flaring.
12. MTX must be withold in serious and opportunistic infections. 3 C 8.9 (1.6)
In mild community-acquired infections, there is no evidence that
MTX should be discontinued.
13. Screening for tuberculosis should ideally be performed in all 5 D 8.4 (1.8
patients with immune-mediated inflammatory diseases at
diagnosis or before starting immunosuppressive therapy.
Screening is based on clinical history, chest x-ray and tests for
immunological memory against Mycobacterium tuberculosis
(both tuberculin skin test and interferon-g release assay).
These patients must be referred to a pulmonologist and, when
indicated, begin tuberculosis treatment adjusted to patients’
immunosuppressive state.
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to parenteral treatment, thus further supporting that
parenteral MTX should be tried in all RA patients un-
responsive to oral therapy prior to treatment with anti-
tumor necrosis factor (anti-TNF) therapy12.
The efficacy and safety of oral (n=187) versus SC
(n=188) administration of the same dose of MTX (15
mg/week) were assessed in a six-month RCT13 and it
was found that starting SC MTX was more effective
than oral administration, with ACR20 and ACR70 res -
ponses at six months significantly higher in the SC
MTX group (78% versus 70% and 41% versus 33%,
respectively; p<0.05), with no increase in side effects.
Remarkably, gastrointestinal AEs were similar between
the two groups.
rEcOMMENDAtION 3
Is folic/folinic acid supplementation to MTX
useful in reducing toxicity for adult patients
with RA? What is the most effective regimen?
Folic acid supplementation is strongly indicated for
reducing GI side effects of MTX, particularly
transami nases elevation, in a recommended dose of
5-10 mg in one to two doses per week. Folinic acid
seems to have the same efficacy as folic acid, but with
a higher cost, making it a less cost-effective treatment.
There is no data regarding the ideal time interval
between MTX and folic acid administration.
Protective effect of folic and folinic acid is fully recogni -
zed in patients with RA treated with MTX. According to
a SLR, including six RCT, folic and folinic acid are asso-
ciated with a statistically significant reduction in the in-
cidence of transaminases elevation (RR 0.19, 95% CI
0.1-0.36 and RR 0.27, 95% CI 0.16-0.44, respectively),
without reducing MTX efficacy14. Besides, both drugs
have shown a trend towards a reduction in GI side effects
and stomatitis, although not statistically significant14.
Analysis of hematologic side effects was not possible, as
this outcome was poorly reported in the studies inclu -
ded14. In this SLR, no evidence of a signifi cant difference
between folic and folinic acid was found and the authors
state that due to similar efficacy outco mes, folic acid low-
er cost makes it a more cost-effective drug14.
Regarding folic acid dose, an inception-cohort on
early RA patients starting MTX (n=347) demonstrated
that supplementation with 10 mg folic acid weekly (in
one to two doses) is associated with a higher hazard of
GI complaints when compared to 1 mg daily (HR = 4.2
[1.25-14.13])15. For liver enzyme abnormalities, no sig-
nificant difference was found, although a trend towards
higher risk of liver enzyme abnormalities in the bi-
weekly dosage group was observed15. In a RCT, com-
paring supplementation with folic acid at a 10 mg dose
per week (n=51) vs. 30 mg per week (n=49) there was
no additional benefit of a higher dose of folic acid, re-
garding the presence of undesirable symptoms (in-
cluding GI), development of cytopenia and transami-
nases elevation16.
rEcOMMENDAtION 4
What is the optimal safety monitoring of
patients with MTX? How frequent should it be
repeated?
After four to six weeks of treatment beginning or escalation,
ALT, AST, CBC and creatinine should be performed. There-
after, if a stable dose of MTX is reached, the same analytical
evaluation should be performed every three to four months.
Clinical assessment should be performed at each visit.
Pulmonary function tests (PFTs) are not recommen ded
on a routine basis, neither previous to MTX-treatment
start, nor during therapy. 
Acute pneumonitis can occur at any time during MTX
therapy and rheumatologists need to be constantly
aware of it. Although its exact incidence is difficult to
determine, it is estimated to occur in 0.3 to 8% of the
MTX-treated patients17.
Lung function screening remains a controversial is-
sue. In a 6-month prospective study, in which spirome -
try was performed at the beginning of the study, patients
who developed MTX pneumonitis were found to have
no abnormalities at treatment baseline17. The main ben-
efit from this exam was to detect patients that have co-
morbidities, such as chronic obstructive pulmo nary dis-
ease, that further decrease pulmonary function17. High-
-resolution computerized tomography (HRCT) request
was determined by clinical findings (respiratory sym -
ptoms, chest x-ray and spirometry)17. A SLR also con-
cluded that changes in PFT did not predict the occur-
rence of MTX-induced pneumonitis and should rather
be performed in patients with new onset dyspnoea to
differentiate it from other clinical conditions18.
Therefore, the diagnosis of MTX-induced lung toxi -
city should be based on a combination of clinical and
imaging data, including the response to drug cessation.
Chest x-ray and HRCT usually show diffuse interstitial
infiltrates and patchy ground-glass opacities and PFTs
depicts evidence of a restrictive pattern, with decreased
carbon monoxide diffusing capacity18. Bronchoalveolar
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elastography and liver biopsy (when elastography score
was >7.9 kPa). The authors found that the cumulative
dose of MTX did not have a significant impact on ALT
elevation or elastography results19. Features of non-al-
coholic steatohepatitis were found in 61.5% of the pa-
tients submitted to liver biopsy, irrespective of the MTX
cumulative dose, and only two had chronic liver disea -
se lesions associated with mild fibrosis (one case and
one control)19.
A prospective study on patients with psoriatic arthri-
tis and psoriasis did not show any significant associa-
tion between MTX dosing, treatment duration, cumu-
lative dose or disease duration and hepatic fibrosis20.
Patients with MTX cumulative dose superior to 1g were
submitted to liver biopsy, but only 36.2% had patho-
logical changes. Liver fibrosis appeared to be more like-
ly among patients with higher number of hepatotoxi-
city predisposing factors (diabetes mellitus, obesity and
alcohol consumption; p=0.01)20.
One retrospective study demonstrated a significant
association between liver stiffness (assessed by elasto -
graphy) and MTX cumulative dose/treatment duration
(p<0.001)21.
These studies highlight that although transamina ses
still play an important role in hepatotoxicity monito -
ring, elastography is coming up as an eligible non-in-
vasive method for evaluating liver stiffness (as a mar -
ker of fibrosis) and can help the decision for liver bio -
psy. Liver biopsy should only be considered in the case
of persistently elevated transaminase levels or increased
elastography values, after risk-benefit evaluation with
a hepatologist.
rEcOMMENDAtION 6
What is the long-term safety of methotrexate,
including cardiovascular diseases, malignancies,
infections and liver toxicity?
MTX can be used for long-term treatment and its use
is safe as far as risk of infectious and cardiovascular
diseases is concerned. Surveillance of pulmonary toxi -
city and of lymphoproliferative disorders (LPD) is
advi sed.
Patients with RA have higher mortality rate as com-
pared to the general population. However, MTX use
for more than one year was associated with a reduction
in the mortality rate (adjusted total HR 0.3 [0.09-
-1.03])22. Similar results were presented on a pros pec -
tive study, in which current treatment strategies for ear-
ly RA, such as MTX monotherapy or in combination
lavage shows frequently an increase in the number of
CD4 lymphocytes and CD4/CD8 ratio and is useful to
rule out infection; lung biopsy is not required in most
cases18.
Lung toxicity can also be raised when MTX dosage
is not adjusted to renal function. Creatinine clearance
should be determined or estimated previously and du -
ring therapy, in order to perform dosage adjustment, if
needed (Figure 2).
rEcOMMENDAtION 5 
What are the indications for pausing/stopping/
/restarting MTX in case of elevated liver tests
and when is liver biopsy indicated?
MTX should be transiently stopped or its dose lowered if
AST and/or ALT is greater than two times the upper limit
of normal (ULN) in three consecutive monthly laborato rial
evaluations (other causes of transaminase elevation must be
ruled out). MTX can be reinstituted after transaminase le -
vels return to normal. MTX should never be readministered
to patients with clinical hepatitis without any other appa -
rent cause, in whom transaminase levels remain persistently
elevated even after MTX temporary discontinuation. 
Liver fibrosis is more likely in patients taking MTX if
concomitant predisposing factors for hepatotoxicity
are present, including diabetes mellitus, obesity and
alcohol consumption. Therefore, these patients should
be carefully monitored, and modifiable risk factors
corrected. Treatment decision should be taken in col-
laboration with a hepatologist. 
Liver toxicity after prolonged treatment with MTX has
been extensively described and is one of the most con-
cerning adverse effects of this therapy, although severe
liver fibrosis rarely occurs19. In a case control-study in-
cluding patients with inflammatory diseases treated
with MTX (cases) and before beginning treatment (con-
trols), liver fibrosis was evaluated by transaminases,
Creatinine % of dose to 





FIGUrE 2. MTX dose adjustment according to creatinine
clearance. (Adapted from Kintzel PE and Dorr RT, “Anticancer
Drug Renal Toxicity and Elimination: Dosing Guidelines for
Altered Renal Function”, Cancer Treat Rev, 1995, 21(1):33-64)
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with other csDMARDs, decreased the excess mortality
risk in RA patients23.
In a prospective study, the three-year incidence of
cardiovascular disease (CVD) (fatal and non-fatal) was
two-fold higher in RA patients when compared to the
general population (HR: 1.9 [1.24-3.05])24and the ma -
gnitude of the risk was comparable with type 2 dia be -
tes24. Importantly, MTX use was associated with a signi -
fi cant reduction of CVD risk (OR: 0.73 [0.7-0.77];
p<0.001)25.
RA patients have a higher risk of being hospitalized
when compared to the general population26. In one
study with a total of 27 710 RA patients, 92% had at
least one mild infection (requiring a physician visit or
use of antibiotics) and 18% had one serious infection
(requiring hospitalization)27. However, MTX use (with-
out concomitant use of oral steroids) was not associa -
ted with higher infection-rates when compared to o ther
csDMARDs27, being even described in some studies a
reduction of the risk of infections requiring hospitali -
zation (HR = 0.76 [0.67-0.86])26.
Pulmonary toxicity of MTX can occur even after
long-term use and is a serious and potentially life-
-threat ening AE. When comparing MTX with lefluno-
mide after two years of use, the risk of adverse respira-
tory events tends to be higher with leflunomide (RR
1.24 [0.83-1,85])28.
MTX has also been recognized as a LPD-inducing
drug. RA patients with LPDs have a worse 5-years sur-
vival rate (p<0.05) when compared with patients wi -
thout RA29. Besides, the association between Eps -
tein–Barr virus (EBV) infection and LPDs is significantly
more common among RA patients29,30. According to a
retrospective cohort study, MTX is associated with a
standardized incidence of LPDs of 8.2130, and there are
even some cases of spontaneous regression after MTX
withdrawal29,30. Patients treated with MTX tend to have
shorter interval between RA at LPDs diagnosis29,30, but
clinicopathological characteristics and 5-year survival
rates in RA patients are similar irrespective of MTX29.
Therefore, although studies outline MTX as a possible
LPD-inducing drug, the risk seems to be higher with
other immunosuppressive drugs, particularly cyclo -
phos phamide31.
rEcOMMENDAtION 7
What is the difference between MTX
combination therapy vs. monotherapy in terms
of efficacy and toxicity in RA?
In DMARD-naive patients, treatment should start with MTX
monotherapy over combination with other csDMARDs, 
taking into account the efficacy/toxicity balance; 
MTX should be considered as the anchor for combination
therapy when MTX monotherapy does not achieve disease
control.
In early RA consider implementation of a tight control
and rapid step-up strategy with MTX plus low-dose
prednisolone (PDN) (≤ 10mg/day) for up to six
months. 
The addition of PDN 10 mg/day at the start of MTX
therapy in early RA decreases erosive joint damage and
further enhances clinical efficacy, without increasing
the risk of AEs, after two years of treatment. Early sus-
tained remission and decreased need for further treat-
ment (SC MTX, cyclosporine or biologic agents) was
observed in the combination group (MTX plus PDN)
as compared to the monotherapy group. Thus this
study supports the implementation of a tight control,
rapid step-up strategy with MTX plus low-dose PDN
(6.25-10 mg)32.
Additionally, clinical disease activity measures and
ultrasonographic (US)-defined remission rates were
compared in early RA patients33 on MTX monotherapy
or combination therapy (MTX plus low-dose [6.25
mg/day] oral PDN). The proportion of patients achiev-
ing clinical remission (DAS28 <2.6) and the probabi -
lity of power Doppler (PD) negativity were signifi -
cantly higher in the MTX + PDN group at one year of
follow-up, with negligible side effects attributable to
PDN. Most of the PDN benefits on DAS28 response
were explained by significantly greater, faster and per-
sistent control over time of the acute-phase reactant
serum levels. As the persistency of a positive PD signal
is the main predictor of early relapse and radiographic
progression in patients in clinical remission, the high-
er effect of PDN on PD may justify the long-term ben-
eficial effect on structural damage33.
rEcOMMENDAtION 8
Is MTX effective as a glucocorticoid-sparing
(adjuvant) treatment in chronic inflammatory
rheumatic disorders, such as PMR, SLE,
vasculitis, PM, DM?
MTX can be considered as a steroid-sparing agent in giant-
-cell arteritis, PMR, SLE and juvenile DM. 
According to a five-year RCT, patients with PMR trea -
ted with PDN and MTX 10 mg/week (n=29) achieved
lower erythrocyte sedimentation rate and C-reactive
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protein values than those treated with corticosteroids
and placebo (n=28; p=0.04)34. However, there was no
significant difference in the prednisone cumulative
dose (p=0.6)34.
In another 12-month RCT, MTX (starting dose 7.5
mg/week up to a maximum 20 mg/week) was associa -
ted with a significant reduction in corticosteroids dose
(p=0.01) in 86 patients with moderately active SLE (41
treated with MTX and 45 with placebo)35. Similar re-
sults were also found in a small open-labelled prospec-
tive controlled study, in which SLE patients treated with
MTX (7.5 mg/week) and PDN (n=30) had a higher re-
duction in PDN dose (p<0.05) and in systemic lupus
erythematosus disease activity index (p<0.001) than
those treated with corticosteroids and placebo (n=18)36.
There were no studies comparing MTX with other
csDMARD as steroid-sparing agents.
rEcOMMENDAtION 9
What is the optimum MTX dose in RA patients
in the perioperative period in order to minimize
perioperative morbidity, while maintaining
disease control?
MTX can be safely continued in the perioperative period in
RA patients undergoing elective orthopaedic surgery.
There is still no data available regarding MTX dose
management in patients undergoing (non-) elective
non-orthopaedic surgery. 
A previous RCT (2001) with 388 patients has shown
that maintaining MTX therapy during orthopaedic
surgery did not increase the risk of infection or surgi-
cal complications in patients with RA within one year
after surgery37. The long-term extension of this study
(up to 10 years) has also shown no increase in the in-
cidence of late postoperative complications or infec-
tions in any patient group. Thus, as previously advised,
in the absence of renal failure or sepsis, MTX therapy
should not be stopped before elective orthopaedic
surgery in patients with RA whose disease is adequate-
ly controlled37.
rEcOMMENDAtION 10
How should MTX be managed when planning
pregnan cy (male and female patients), during pre -
gnancy and after pregnancy?
We recommend MTX suspension at least three months be-
fore conception, during pregnancy and breastfeeding. In
men, when MTX therapy is unavoidable, there is re-
cent evidence that MTX does not need to be stopped
before conception.
Previous use of MTX was not associated with fertility
problems in female and male RA patients, as assessed
by time to pregnancy.
A nationwide prospective cohort study (the PARA study)
evaluated fertility of female RA patients, including wo -
men preconceptionally or during the first trimester38.
Previous use of MTX did not have a measurable effect
on time to pregnancy, while therapy with nonsteroidal
anti-inflammatory drugs and oral PDN (>7.5 mg/day)
was associated with longer time to pregnancy38.
According to an observational study, Food and Drug
Administration (FDA) categories D and X medications’
prescription were higher in women with spontaneous
abortions, particularly MTX (p<0.05)39.
Similar data was demonstrated by a multicenter
study, including pregnancies with pre and post-con-
ception exposure to MTX that were compared to disea -
se-matched women and women without autoimmune
diseases40. In this study, MTX was associated with hi -
gher rates of spontaneous abortions, but only in the
post-conception group and there was a significantly in-
creased risk of major birth defects in the MTX post-
-conception group compared to the general population
(OR: 3.1). However, the number of pregnancies with
pre-conception MTX exposure included in this study
was limited40. Therapy with other csDMARDs and/or
oral steroids did not significantly increase this risk40.
Regarding males, an observational cohort study in-
cluding 525 patients (113 with paternal low-dose MTX
exposure and 412 non-exposed) found no evidence for
an increased risk of adverse pregnancy outcomes after
paternal MTX exposure (<30 mg) in patients with RA
and other inflammatory arthropathies, including ma-
jor birth defects and spontaneous abortions41. Though
this result needs further confirmation, this study sug-
gests that in cases of unavoidable MTX therapy in
males, postponing conception might not be necessary.
rEcOMMENDAtION 11
How should we manage MTX dosing after
achieving clinical remission?
A gradual dose reduction to the lowest effective MTX
dose may be attempted after achieving sustained clini -
cal remission for at least 6 months, with clinical and
radiological monitoring. 
In some early RA patients in remission, drug-free
remission (DFR) may be achieved, but it could be as-
sociated with an increased risk of flaring. 
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The evidence underlying the effect of MTX tapering
and withdrawal on disease outcomes in RA patients is
somewhat limited, generally restricted to small obser-
vational studies and clinical trials conducted in the
1980s and 1990s, in patients with established RA42. A
2015 SLR42 do not support the practice of complete
MTX monotherapy withdrawal, which is associated
with a significantly increased risk of flaring.
In the BeSt study43 508 patients with recent-onset
(p=0.14). The treatment strategy was not indepen-
dently associated with DFR. The mean duration of DFR
at four years was 11 months. Patients achieving DFR
appeared to have milder RA at baseline. However,
among these patients, 69% had erosive disease at base-
line, 52% and 43% were rheumatoid factor (RF) and
anti citrullinated protein antibodies (ACPA) positive,
at baseline. ACPA negativity, male gender and short
symptom duration were independently associated with
DFR at four years43. After five years, 23% of the 508
patients achieved DFR with no significant differences
between all treatment groups44. However, almost half
of these (46%) had to restart treatment after a median
period of five (2-16) months, but the majority (47%)
of the ‘restarters’ re-achieved clinical remission within
three to six months and with no further structural da -
mage progression. ACPA positivity was the strongest
independent predictor for restarting treatment. 30% of
the patients with sustained DFR were ACPA positive44.
The IMROVED45 study evaluated how often remis-
sion or even DFR could be achieved in 610 patients
with early RA or undifferentiated arthritis (UA) that
started treatment with MTX and PDN. After 1 year, of
the 61% of patients who started tapering medication af-
ter being in remission (DAS <1.6) at 4 months, 68%
were in remission and 32% in DFR. After 2 years46 49%
and 23% were in DAS-remission and ACR/EULAR re-
mission, respectively, but significantly more UA pa-
tients, of whom 94% were ACPA-negative, achieved
DFR compared to RA patients (34% and 19%, respec-
tively).
The follow-up study of Rotterdam Early Arthritis
Cohort47 investigated the frequency and time to remis-
sion and subsequent tapering of csDMARDs and bio-
logic (b)DMARDs and the frequency and time to flare
and regained remission in patients tapering therapies.
281 patients with early arthritis (<1 year) were ran-
domized for induction treatment strategies with triple
DMARD therapy (MTX 25mg/week, SSZ 2000mg/day
and HCQ 400mg/day) or MTX monothe rapy
(25mg/week) and if sustained remission was achieved
with DAS <1.6 at 2 consecutive visits (every 3 months),
medication was tapered while remission remained.
During 2 years of follow-up, sustained remission was
achieved in 57% of patients. Of 118 patients tapering
csDMARDs, 44% experienced a flare during the 2-year
follow-up and, after flare, 53% (95% CI 40% to 68%)
of patients tapering csDMARDs regained DAS-remis-
sion within 3 months and 65% (95% CI 50% to 79%)
within 6 months, after treatment intensification. 
To the best of our knowledge, there are no other
studies that have evaluated the effect of tapering MTX
monotherapy dosage on RA outcomes, although this is
undertaken in clinical practice.
rEcOMMENDAtION 12
How should we manage MTX during infections?
MTX must be withhold in serious and opportunistic infec-
tions. In mild community-acquired viral infections, there is
no evidence that MTX should be discontinued.
New studies reinforced the idea that MTX continua-
tion is safe in mild infections (such as viral infections,
not requiring antibiotics)48. On the other hand, in se-
vere bacterial infections, with hospital admission and
intravenous antibiotics, MTX must be suspended un-
til antibiotic treatment is concluded, symptoms re-
solved and inflammatory parameters returned to base-
line48.
Regarding possible interactions with antibiotics,
trimethoprim-sulfamethoxazole (TMP-SMX) was
found to be an important risk factor for developing
bone marrow suppression49. As MTX, TMP-SMX in-
hibits dihydrofolate reductase, thus potentiating bone
marrow toxicity. The duration of antibiotic treatment
before the finding of cytopenias ranged from two days
to two months, with the majority of cytopenias occur-
ring within the first two weeks49. Therefore, TMP-SMX
should not be used for treatment of cystitis in patients
receiving MTX. There are no reported cases of this se-
rious AE with the regimen used for Pneumocystis jirove-
ci prophylaxis 3 times/week. There is no information
regarding the possible “protective” effect of folic acid in
this situation49.
rEcOMMENDAtION 13
How should we screen for and treat tuberculosis
in patients on MTX?
Screening for tuberculosis should ideally be performed
in all patients with immune-mediated inflammatory
diseases at diagnosis or before starting immunosu -
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ppressive therapy. Screening is based on clinical his-
tory, chest x-ray and tests for immunological memo-
ry against Mycobacterium tuberculosis (both tuber-
culin skin test and interferon-g release assay). 
These patients must be referred to a tuberculosis
expert and, when indicated, begin tuberculosis treat-
ment adjusted to patients’ immunosuppressive state.
In Quebec, a case-control study reported an incidence
rate of tuberculosis (TB) 10 times higher in RA patients,
when compared to the general population50. When try-
ing to evaluate possible effects of RA therapy, a nested
case-control analysis demonstrated an adjusted risk-
-ratio for developing TB in the year prior to the index
date of 3.4 in MTX-users as compared to control sub-
jects50.
Given the increased risk of TB, all patients with im-
mune-mediated inflammatory diseases should be
screened for TB when the disease is diagnosed and,
most importantly, before starting any immunosup-
pressive therapy. Indeed, chronic immunosuppressive
therapy (including > 15 mg/day of PDN for more than
two weeks) compromises the sensitivity of tuberculin
skin test (TST) and interferon-g release assay (IGRA),
screening51. Screening includes a detailed medical his-
tory, chest x-ray, TST and IGRA. Compared to the TST,
IGRA is more specific and sensitive, especially after
starting immunosuppressive therapy. On the other
hand IGRA is more expensive52.
Patients are eligible for latent TB treatment accor -
ding to their immunosuppressive state and TST and
IGRA results, as advised in the position paper on tu-
berculosis screening in patients with immune media -
ted inflammatory diseases candidates for biological
therapy51.
Regarding the safety of TB treatment, co-treatment
with MTX and isoniazid (INH 300 mg/day with pyri-
doxine at 50 mg/day) was associated with a transient
LFT elevation similar to patients treated with MTX
without hepatotoxic co-treatment (less than twice the
ULN values), with no need to stop medication53. There
were no reported cases of severe hepatotoxicity or
hepa tic failure53.
cONcLUsION
The thirteen recommendations were updated after a
careful systematic review of the literature published
since 2009 and agreement among Portuguese rheuma-
tologists. Therefore, they constitute a useful tool in dai-
ly practice, helping professionals to improve the care
for patients with rheumatic diseases. However, it
should be mentioned that some of the data presented
was based on retrospective studies or expert opinion
and must be analysed carefully. In addition, new data
presented, such as MTX management during pregnan-
cy and breastfeeding or association between MTX and
LPD, are particularly interesting and relevant, but evi-
dence is still scarce to achieve definite conclusions. 
There are some limitations in these recommenda-
tions that the authors would like to outline. In some ar-
ticles regarding long-term safety or hepatotoxicity man-
agement, folic acid use is not mentioned or the dose is
not specified. Moreover, in the recommendation about
the most effective regimen of folic acid, one of the stu -
dies included refers to the use of 1 mg daily, although
this dose is not available in Portugal.
The authors would like to reinforce the importance
of updating recommendations for the use of MTX in
rheumatic diseases on a regular basis, as MTX is one of
the most effective, and probably the most commonly
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